Teprotumumab for the Treatment of Active Thyroid Eye Disease
Original Article
R.S. Douglas, G.J. Kahaly, A. Patel, S. Sile, E.H. Thompson, R. Perdok, J.C. Fleming, B.T. Fowler, C. Marcocci, M. Marinò, A. Antonelli, R. Dailey, G.J. Harris, A. Eckstein, J. Schiffman, R. Tang, C. Nelson, M. Salvi, S. Wester, J.W. Sherman, T. Vescio, R.J. Holt, and T.J. Smith
N Engl J Med 2020;382:341-352
Course summary
Available credit:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course opens:
01/22/2020
Course expires:
01/23/2022
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Course closed
This course closed on Sunday, January 23, 2022 - 11:59pm.

Facebook
X
LinkedIn
Forward